2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task …
GN Levine, ER Bates, JC Blankenship… - Journal of the American …, 2011 - jacc.org
Interventions. Copies: This document is available on the World Wide Web sites of the
American College of Cardiology (www. cardiosource. org), the American Heart Association …
American College of Cardiology (www. cardiosource. org), the American Heart Association …
[PDF][PDF] 2016 European Guidelines on cardiovascular disease prevention in clinical practice
MF Piepoli, AW Hoes, S Agewall… - Polish Heart …, 2016 - journals.viamedica.pl
2.3. 9. Wnioski................................................ 838 2.4. Inne markery ryzyka.......................................
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias
AL Catapano, I Graham, G De Backer… - Polish Heart …, 2016 - journals.viamedica.pl
5.1. Wpływ stylu życia na stężenie cholesterolu całkowitego i stężenie cholesterolu frakcji
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study
J Escaned, C Collet, N Ryan… - European heart …, 2017 - academic.oup.com
Aims To investigate if recent technical and procedural developments in percutaneous
coronary intervention (PCI) significantly influence outcomes in appropriately selected …
coronary intervention (PCI) significantly influence outcomes in appropriately selected …
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC …
A substantial number of chronic coronary syndrome (CCS) patients undergoing
percutaneous coronary intervention (PCI) experience periprocedural myocardial injury or …
percutaneous coronary intervention (PCI) experience periprocedural myocardial injury or …
Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial
Background: Vascular injury and inflammation during percutaneous coronary intervention
(PCI) are associated with increased risk of post-PCI adverse outcomes. Colchicine …
(PCI) are associated with increased risk of post-PCI adverse outcomes. Colchicine …
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American …
Writing Committee Members*, GN Levine, ER Bates… - Circulation, 2011 - Am Heart Assoc
The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted through November 2010, as well as selected …
extensive evidence review was conducted through November 2010, as well as selected …
Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the …
O Berwanger, EV Santucci, I de Andrade Jesuíno… - Jama, 2018 - jamanetwork.com
Importance The effects of loading doses of statins on clinical outcomes in patients with acute
coronary syndrome (ACS) and planned invasive management remain uncertain. Objective …
coronary syndrome (ACS) and planned invasive management remain uncertain. Objective …
Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non–ST-segment elevation myocardial infarction …
JC Tardif, JF Tanguay, SR Wright, V Duchatelle… - Journal of the American …, 2013 - jacc.org
Objectives: The study aimed to evaluate inclacumab for the reduction of myocardial damage
during a percutaneous coronary intervention (PCI) in patients with non–ST-segment …
during a percutaneous coronary intervention (PCI) in patients with non–ST-segment …